The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Open accessAbstract
Irinotecan (CPT-11) is a promising antitumor agent, recently approved for use in patients with metastatic colorectal cancer. Its active metabolite, SN-38, is glucuronidated by hepatic uridine diphosphate glucuronosyltransferases (UGTs). The major dose-limiting toxicity of irinotecan therapy is diarrhea, which is believed to be secondary to the biliary excretion of SN-38, the extent of which is determined by SN-38 glucuronidation. The purpose of this study was to identify the specific isoform of UGT involved in SN-38 glucuronidation. In vitro glucuronidation of SN-38 was screened in hepatic microsomes from normal rats (n = 4), normal humans (n = 25), Gunn rats (n = 3), and patients (n = 4) with Crigler-Najjar type I (CN-I) syndrome. A wide intersubject variability in in vitro SN-38 glucuronide formation rates was found in humans. Gunn rats and CN-I patients lacked SN-38 glucuronidating activity, indicating the role of UGT1 isoform in SN-38 glucuronidation. A significant correlation was observed between SN-38 and bilirubin glucuronidation (r = 0.89; P = 0.001), whereas there was a poor relationship between para-nitrophenol and SN-38 glucuronidation (r = 0.08; P = 0.703). Intact SN-38 glucuronidation was observed only in HK293 cells transfected with the UGT1A1 isozyme. These results demonstrate that UGT1A1 is the isoform responsible for SN-38 glucuronidation. These findings indicate a genetic predisposition to the metabolism of irinotecan, suggesting that patients with low UGT1A1 activity, such as those with Gilbert's syndrome, may be at an increased risk for irinotecan toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N. J., Jansen, P. L. M., Elferink, R. P. J. O., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331802 · Cited by 1,447
Chen, C. A., & Okayama, H. (1988) · PubMed · Cited by 894
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
Monaghan, G., Ryan, M., Hume, R., Burchell, B., & Seddon, R. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91273-8 · Cited by 585
CONGENITAL FAMILIAL NONHEMOLYTIC JAUNDICE WITH KERNICTERUS
Crigler, J. F., & Najjar, V. A. (1952) · PEDIATRICS · doi:10.1542/peds.10.2.169 · Cited by 548
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., & Ratain, M. J. (1994) · PubMed · Cited by 501
Self-citationHuman UGT2B7 catalyzes morphine glucuronidation.
Coffman, B. L., Rios, G. R., King, C. D., & Tephly, T. R. (1997) · PubMed · Cited by 481
Self-citationBosma, P. J., Seppen, J., Goldhoorn, B., Bakker, C., Oude Elferink, R. P., Chowdhury, J. R., Chowdhury, N. R., & Jansen, P. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32403-1 · Cited by 446
Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410
Cited by
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Self-citationDelivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Self-citationAlmazroo, O. A., Miah, M. K., & Venkataramanan, R. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.08.001 · Cited by 681
Wang, L., McLeod, H. L., & Weinshilboum, R. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1010600 · Cited by 613
Enzyme-Catalyzed Activation of Anticancer Prodrugs
Rooseboom, M., Commandeur, J. N. M., & Vermeulen, N. P. E. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.3 · Cited by 497
Pharmacogenomics of human UDP-glucuronosyltransferase enzymes
Guillemette, C. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500171 · Cited by 425
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“UGT1A1 also conjugates bilirubin, and a significant correlation between SN-38 and bilirubin glucuronidation has been observed [42].”
BackgroundIrinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response
Evans, W. E., & Johnson, J. A. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.9 · Cited by 415
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Glucuronidation in Humans: Pharmacogenetic and Developmental Aspects
de Wildt, S. N., Kearns, G. L., Leeder, J. S., & van den Anker, J. N. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00005 · Cited by 393
The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
Meech, R., Hu, D. G., McKinnon, R. A., Mubarokah, S. N., Haines, A. Z., Nair, P. C., Rowland, A., & Mackenzie, P. I. (2019) · Physiological Reviews · doi:10.1152/physrev.00058.2017 · Cited by 368
Gagné, J.-F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., & Guillemette, C. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.608 · Cited by 346
Toffoli, G., Cecchin, E., Corona, G., Russo, A., Buonadonna, A., D'Andrea, M., Pasetto, L. M., Pessa, S., Errante, D., De Pangher, V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5400 · Cited by 338
Genetic susceptibility to adverse drug reactions
Pirmohamed, M., & Park, B. K. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01717-x · Cited by 328
Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., & Tamai, I. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001909 · Cited by 316
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
Marcuello, E., Altés, A., Menoyo, A., del Rio, E., Gómez-Pardo, M., & Baiget, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602042 · Cited by 315
Han, J.-Y., Lim, H.-S., Shin, E. S., Yoo, Y.-K., Park, Y. H., Lee, J.-E., Jang, I.-J., Ho Lee, D., & Soo Lee, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0239 · Cited by 298
Iyanagi, T. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(06)60002-8 · Cited by 290
Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Capela, J. P., Carmo, H., Remião, F., Bastos, M. L., Meisel, A., & Carvalho, F. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8064-1 · Cited by 290
Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, J.-I., Hamaguchi, T., Yamamoto, N., et al. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328014341f · Cited by 289
Inherited disorders of bilirubin metabolism
Bosma, P. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00359-8 · Cited by 279
Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity
Rouits, E., Boisdron-Celle, M., Dumont, A., Guérin, O., Morel, A., & Gamelin, E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0548 · Cited by 276
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 266
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 262
Self-citationCarlini, L. E., Meropol, N. J., Bever, J., Andria, M. L., Hill, T., Gold, P., Rogatko, A., Wang, H., & Blanchard, R. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1226.11.3 · Cited by 262
GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE
Wells, P. G., Mackenzie, P. I., Roy Chowdhury, J., Guillemette, C., Gregory, P. A., Ishii, Y., Hansen, A. J., Kessler, F. K., Kim, P. M., Roy Chowdhury, N., et al. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.3.281 · Cited by 260
SAI, K. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.01.010 · Cited by 257
Prados, M. D., Lamborn, K., Yung, W. K. A., Jaeckle, K., Robins, H. I., Mehta, M., Fine, H. A., Wen, P. Y., Cloughesy, T., Chang, S., et al. (2006) · Neuro-Oncology · doi:10.1215/15228517-2005-010 · Cited by 254
Strassburg, C. P. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.07.007 · Cited by 184
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., Wang, Y. W., Yeh, C. G., Chiang, N. J., Chang, J. Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2671-x · Cited by 100
Kong, R., Liu, T., Zhu, X., Ahmad, S., Williams, A. L., Phan, A. T., Zhao, H., Scott, J. E., Yeh, L.-A., & Wong, S. T. C. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0395 · Cited by 90
“SN38 undergoes further metabolism in both liver and intestine by UDT-glucuronosyltransferase (UGT), which conjugates it with glucuronic acid to form the inactive SN-38G (6, 7).”
BackgroundA phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
INNOCENTI, F., UNDEVIA, S., RAMIREZ, J., MANI, S., SCHILSKY, R., VOGELZANG, N., PRADO, M., & RATAIN, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.016 · Cited by 57
Self-citation
Metadata
- Authors
- Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K., Tephly, T. R., Coffman, B. L., & Ratain, M. J.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-15
- Volume
- 101
- Issue
- 4
- Pages
- 847-854
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2021622287
- Cited by
- 686
- References
- 37
- FWCI
- 20.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.